Antimicrobial activity of recombinant Pg-AMP1, a glycine-rich peptide from guava seeds  by Tavares, Letícia Stephan et al.
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Antimicrobial  peptides  (AMPs)  are  compounds  that  act in  a wide  range  of  physiological  defensive  mech-
anisms  developed  to counteract  bacteria,  fungi,  parasites  and  viruses.  These  molecules  have  become
increasingly  important  as  a  consequence  of  remarkable  microorganism  resistance  to common  antibi-
otics.  This  report  shows  Escherichia  coli  expressing  the  recombinant  antimicrobial  peptide  Pg-AMP1
previously  isolated  from  Psidium  guajava  seeds.  The  deduced  Pg-AMP1  open  reading  frame  consists  in
a 168  bp  long  plus  methionine  also  containing  a His6  tag,  encoding  a predicted  62  amino  acid  residue
peptide  with  related  molecular  mass  calculated  to be  6.98  kDa  as  a monomer  and  13.96  kDa  at  the  dimerntimicrobial peptides
eterologous expression
sidium guajava
form.  The  recombinant  Pg-AMP1  peptide  showed  inhibitory  activity  against  multiple  Gram-negative
(E.  coli,  Klebsiella  pneumonia  and  Pseudomonas  aeruginosa)  and  Gram-positive  (Staphylococcus  aureus  and
Staphylococcus  epidermides)  bacteria.  Moreover,  theoretical  structure  analyses  were  performed  in  order
to understand  the  functional  differences  between  natural  and  recombinant  Pg-AMP1  forms.  Data  here
reported  suggest  that  Pg-AMP1  is  a promising  peptide  to be  used  as  a biotechnological  tool  for  control  of
s.human  infectious  disease
. IntroductionIn recent years, the number of bacteria with enhanced resis-
ance to conventional antibiotics has dramatically increased [10].
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Many hospital infections have been difﬁcult to treat due to
opportunistic bacterial infections. Many of these bacteria belong
to regular microbial ﬂora, making them a real challenge for
immune-depressed patients. In general, treatment is expensive and
inefﬁcient, encouraging several research groups to screen novel
antimicrobial compounds [9,40].  Among them, antimicrobial pep-
tides (AMPs) have been focused since they are the ﬁrst natural
barrier against microorganisms from almost all living groups [40].
AMPs are constitutively expressed or induced by endogenous or
exogenous elicitors, such as developmental stage or pathogen pre-
dation [32]. AMPs are small proteins, 20–50 amino acid residues
long, and in some organisms constitute the primary innate host
defense line, often have common properties such as the small
number of amino acid residues, cationicity and amphipathicity
[25]. Although various AMPs have been isolated in different king-
doms, several structural scaffolds are quite common and may  be
related to a single promiscuous class of peptides with multiple
Open access under the Elsevier OA license.functions [8].  The mechanism of action include select electro-
static interactions that may  induce lipid bilayer depolarization,
permeability alterations and ion imbalance [28] that may  lead
to membrane disruption. Moreover, the presence of AMPs could
ptides
a
p
l
a
l
i
[
g
T
e
b
r
i
i
E
b
w
a
i
a
t
r
s
t
e
F
t
a
t
g
t
a
h
m
e
p
r
r
e
s
p
p
o
c
s
m
T
i
c
i
t
f
b
e
s
b
n
s
b
t
t
a
p
lL.S. Tavares et al. / Pe
lso lead to alteration of several gene expressions, improving
rotein synthesis and modifying enzyme activities [32]. In the
ast two decades a number of studies have shown that AMPs
ct synergistically to the immune response [10,23], making iso-
ation, identiﬁcation and characterization of natural AMPs an
mportant tool for development of a new generation of drugs
11,23,39].
Among the AMPs, the glycine-rich proteins (GRPs) are a
roup of proteins that occurs in a wide variety of organisms.
his group carries glycine-rich repeat domains [2,24] and their
xpressions in plants are normally modulated by abiotic and
iotic stresses, showing defensive activity against fungi, bacte-
ia and viruses [2]. Pelegrini et al. [28] demonstrated that a GRP
solated from guava seeds, denominated Pg-AMP1, showed activ-
ty against human pathogenic Gram-negative bacteria such as
scherichia coli, Klebsiella sp. and Proteus sp. In spite of the clear
actericidal activity observed, puriﬁcation and yield of Pg-AMP1
as extremely low, reaching approximately 1 mg  of peptide from
lmost 10 kg of total guava seeds [28]. This protein quantity was
nsufﬁcient to allow novel experiments or to use these peptides
s a biotechnological tool for infectious disease treatment. Fur-
hermore, Pg-AMP1chemical synthesis, a peptide 55 amino acid
esidues long, is extremely expensive, therefore for Pg-AMP1 the
trategy of recombinant protein production in a heterologous sys-
em is essential. However, few articles described heterologous
xpression of recombinant glycine-rich antimicrobial peptides.
eng et al. [7] expressed SK66-His and Sperstad et al. [37] expressed
he GRP-denominated hystatin, that showed deleterious activity
gainst Gram-positive and Gram-negative bacteria and yeasts. Fur-
hermore, Shlyapnikov et al. [36] cloned and expressed a synthetic
ene in a pET vector. This gene, named Ltc2a (latarcin 2a), was fused
o 6 glycine residues and further demonstrated protective activity
gainst E. coli and Bacillus subtilis.
The number of recombinant antimicrobial peptides expressed
as greatly increased in recent years due to advances in
olecular biology, allowing the establishment of strategies for
xpression such as host choice, promoter type and appropriate
ost-transcriptional modiﬁcation features [33]. Bacterial systems
emain highly attractive due to low cost, high productivity and
apid use. Although the bacterial systems seems to be useful for
ukaryotic protein expression some limitations must be overcome,
uch as codon usage, incorrect folding, protein degradation by
rotease from host cell and host toxicity caused by heterologous
rotein [14]. Over-expression of heterologous proteins in E. coli
ften produces high quantities of insoluble protein. In order to over-
ome such limitations, the optimization of expression conditions
uch as temperature, growth media, induction parameters, pro-
oters and E. coli expression strain maybe used [33]. Fusion tags as
rx, NusA, GST, MBP  and His6 were able to increase protein solubil-
ty, improving the puriﬁcation processes by decreasing production
osts and increasing yield [27,31]. Although fusion tags maybe
nteresting since they facilitate peptide solubility and puriﬁcation,
hese tags can also often interfere within protein structure and/or
unction. Consequently, it is commonly recommended that the tag
e removed after the puriﬁcation process [27], although Carson
t al. [3] have shown that the His6 tag does not normally alter the
tructure of recombinant proteins. Tag removal can be performed
y proteolytic cleavage, but this approach can be problematic due to
on-speciﬁc and inefﬁcient cleavage or loss of protein stability and
olubility [27]. Another factor that impairs heterologous antimicro-
ial peptide expression in E. coli is cytotoxic AMP  activity against
he bacterial host. This leads to clear difﬁculties in scale-up and
o low yields processing requires chemicals or expensive enzymes,
nd multistep puriﬁcation of peptides reduces yield, thus making
eptide production less cost effective [1].  In spite of all these prob-
ems, some studies describe the expression of AMPs in prokaryotic 37 (2012) 294–300 295
expression system as E. coli with yielding varying from 2 mg  L−1 to
40 mg  L−1 [18,19,33,38,41].
In the present work the guava GRP gene, named Pg-AMP1,
was synthesized and further expression strategy was  designed
for production of the recombinant peptide in a prokaryotic sys-
tem. Recombinant Pg-AMP1 was further evaluated for biological
activity against human pathogenic bacteria. Moreover, theoret-
ically structural studies comparing the native and recombinant
Pg-AMP1 forms were also carried out to shed some light on
structure–function relationship.
2. Materials and methods
2.1. Bacterial strains
Gram-negative bacteria Escherichia coli (ATCC 35218, ATCC
11229), Pseudomonas aeruginosa (ATCC 27853), Klebsiella pneumo-
nia (ATCC 13866) and Salmonella typhimurium (ATCC 14028) and
Gram-positive bacteria Staphylococcus aureus (ATCC 29213, ATCC
25923), S. aureus MecA (ATCC 33591), Staphylococcus epidermides
(ATCC 12228) were utilized in this report. Bacteria were cultured
in Tryptone Soy Broth (TSB-Tryptone 5 g L−1, yeast extract 2.5 g L−1,
Dextrose 1 g L−1 and sodium chloride 10 g L−1). The induced E. coli
bacteria (BL21-DE3) were cultured in Luria–Bertani broth medium
(LB).
2.2. Gene synthesis and vector construction
The gene encoding Pg-AMP1, 168 bp long, was designed to
be expressed carrying a His6 tag fused to C-terminal. The codon
was optimized for E. coli expression and the cassette expression
was synthesized by Epoch Biolabs and cloned into SmaI site of
pBluescriptIISK(−). The expression cassette is composed of Pg-
AMP1 gene under control of T7/lac promoter/terminator plus met
codon His6 tag encoding a peptide with 62 amino acid residues
(Fig. 1).
2.3. Expression of recombinant Pg-AMP1
Recombinant plasmid pBSKPg-AMP1 was used for transfor-
mation of E. coli BL21 (DE3) electrocompetent cells (Invitrogen,
Carlsbad, CA). The induction was done according to the instruction
manual His Trap FF crude (GE, Upsala), using IPTG as an inducer
and ampicillin (100 g mL−1) as select agent. The IPTG induction
(0, 0.5 and 1 mM)  was  done during 2, 4 or 6 h. Soluble and insoluble
fractions were evaluated in each treatment.
2.4. Isolation of recombinant peptide
BL21 (DE3) cells were grown for 4 h from 500 mL of LB at
300 rpm. Pellet cells were obtained from 4500 × g at 4 ◦C after
15 min  centrifugation. Pellets were resuspended in lysis buffer
(1:10 v/v) containing 50 mM sodium phosphate (pH 7.8), 300 mM
sodium chloride, 50 mM potassium chloride, 10% glycerol, 0.5% Tri-
ton X-100 and 10 mM imidazole. Enzymatic lysis was performed
for 30 min  at room temperature with 0.2 mg mL−1 lysozyme,
20 g mL−1 DNAse, 1 mM MgCl and 1 mM phenylmethylsul-
fonylﬂuoride. Mechanical lysis was  carried out by sonication on
ice for approximately 10 min  (in several short bursts). Suspension
cells were disrupted by sonication (Sonics – Vibra Cell) 20 kHz 100%
using the v188 probe on ice four times for 20 s separated by 1 min
elapsed time. The suspension was  centrifuged at 4500 × g at 4 ◦C for
30 min. Supernatant carrying soluble proteins were stored −20 ◦C
for subsequent analysis. For each gram of pellet, 3 mL of lysis buffer
containing 300 mM sodium chloride, 50 mM  sodium phosphate (pH
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cgcgaaattaatacga ctcactataggg gaattgtgagcg gataacaattcc cctctaga  
aataattttgtttaac tttaagaaggag atatacatatgc gtgagtctccga gtagccgc  
                                     M  R  E  S  P  S  S  R  
atggaatgctatgaac aggcggagcgtt atgggtacggcg gctatggtggcg gtcgttac  
 M  E  C  Y  E  Q  A  E  R  Y  G  Y  G  G  Y  G  G  G  R  Y  
ggcggtggttatggta gcggtcgcggcc agccggttggtc agggcgtggaac gcagccat  
 G  G  G  Y  G  S  G  R  G  Q  P  V  G  Q  G  V  E  R  S  H  
gacgataatcgtaacc aaccacgccatc atcatcatcatc actaactgctaa caaagccc  
 D  D  N  R  N  Q  P  R  H  H  H  H  H  H  * 
gaaaggaagctgagtt ggctgctgccac cgctgagcaata actagcataacc ccttggg g
cctctaaacgggtctt gaggggtttttt gctgaaaggagg aactatatccgg at
Fig. 1. Synthetic cassette sequence Pg-AMP1 showing T7 promoter (Gray) – including Lac operator and ribosome binding site. Coding region including histidine tag terminator
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.4), 10 mM -mercaptoethanol and 10 g mL−1 protease cocktail
nhibitor (SIGMA) was added in order to resuspend insoluble frac-
ion. The suspension was kept at room temperature for 30 min
nd sonicated again for 3× 20 s separated by 1 min  interval on ice.
he suspension was centrifuged at 4500 × g at 4 ◦C for 15 min. The
ellet was treated with two different buffers (A and B) for sus-
ension of insoluble aggregates. Buffer A (6 M Gua–HCl, 300 mM
odium chloride, 50 mM sodium phosphate (pH 7.4) and 20 mM
midazole) and buffer B (8 M urea, 300 mM sodium chloride and
0 mM imidazole) in order to identify the fraction soluble or insol-
ble in which the peptide is located. The suspensions containing
oluble peptides were centrifuged at 4500 × g at 4 ◦C for 15 min
nd the pellet was resuspended in100 L of distilled water. Pro-
ein puriﬁcation was performed by immobilized metal ion afﬁnity
hromatography (IMAC) in a Nickel His-Trap 1 mL  column (GE,
psala) using imidazole in binding buffer (20 mM imidazole) and
luted with imidazole elution buffer (500 mM Imidazole). The clar-
ﬁed lysate was placed in afﬁnity column Crude His Trap FF crude
olumns 1 mL  (GE) for puriﬁcation according to the manufacturer’s
nstructions.
.5. Tricine–SDS-PAGE analyses
Protein samples were electrophoresed in Tricine–SDS-PAGE
16%) under non-denaturating conditions as described by Schagger
34] with minor modiﬁcations. Protein quantiﬁcation was carried
ut according to Lowry [22] and BSA (bovine serum albumin) was
sed as the standard. The Pg-AMP1 (50 g) was mixed with sam-
le buffer Electrophoresis was performed in the Mini-PROTEAN
etra Electrophoresis System® (Bio-Rad). Peptides were ﬁxed and
urther silver stained. Ultra low range molecular weight marker
1.6–26.6 kDa) from SigmaTM and protein marker (2–212 kDa)
New England Biolabs, Ipswich, MA)  was used as standard.
.6. Western blotting
Tris-Tricine–SDS-PAGE gel was electro-blotted for 20 min at
00 V onto an RPN3032D (0.20 m pore size) nitrocellulose mem-
rane (Amersham Hybond-ECL/GE). Membrane was  washed in
BS and blocked by immersing the membrane in PBS-T 0.1%. The
embrane was primarily incubated with anti-His antibody (GE)
1:1000) overnight then washed in PBS-T and incubated with
he secondary antibody (1:1000) diluted in PBS with 3% antibody
nti-mouse IgG peroxidase conjugate (GE) added for 1 h at room
emperature detection was carried out in a dark room using Amer-
ham ECL Prime Western Blotting Detection Reagent (GE) on auto
adiography ﬁlm (Amersham Hyperﬁlm ECL). present.
2.7. Antibacterial assays
Antimicrobial activities of recombinant puriﬁed Pg-AMP1
were tested against the after mentioned Gram-negative and
Gram-positive bacteria. Polypropylene microplates were used to
inoculate 100 L of TSB medium containing the microorganism
(concentration of 5 × 104 CFU mL−1 well−1) and 100 L of Pg-AMP1
recombinant peptide dissolved in saline solution (0.9 g L−1) at dif-
ferent concentrations (25, 50 and 100 g mL−1) to determine the
minimal inhibitory concentration (MIC). Two sets of negative con-
trol were used: (I) bacteria treated with wash buffer 20 mM sodium
phosphate, 500 mM imidazole, sodium 0.5 M chloride (pH 7.4);
(II) saline solution (0.9 g L−1). Chloramphenicol was  used as pos-
itive control at 1000, 100, 50 and 25 g mL−1 dissolved in saline
solution (0.9 g L−1). Each treatment was  performed in triplicate
according to NCCLS [26]. The cell growth was monitored by tur-
bidimetry absorbance at 600 nm using the Elisa Espectra Max
190 (Molecular Devices). In order to determine the bactericidal or
bacteriostatic action of Pg-AMP1, 20 L of each treatment was re-
inoculated in 1 mL  of liquid TSB and incubated for 16 h at 37 ◦C
under 100 rpm and the cell growth was measured by turbidimetry
absorbance at 600 nm using the Elisa Espectra Max 190 (Molecular
Devices).
2.8. Hemolysis assays
Hemolytic activity assays were performed as described by Jang
et al. [15]. Three mL  of fresh human red blood cells (RBCs) was
washed with 9 mL  of sterile isotonic phosphate-buffered saline,
pH 7.4 (PBS), until the color of the supernatant turned clear. The
washed RBCs were then diluted to ﬁnal volume of 20 mL  with the
PBS buffer and 10 L of different solutions of Pg-AMP1 PBS diluted
(200, 100 and 50 g mL−1) was added to 190 L of the cell sus-
pension in 0.5 mL  microfuge tubes. Following the gentle mixing,
the tubes were incubated at 37 ◦C for 30 min  and then centrifuged
at 4000 × g for 5 min. One hundred microliter of supernatant was
taken, diluted to 1 mL  with PBS, and 100 L were removed and
placed in a microplate to be read in Varioskan (Thermo) under
567 nm absorbance and the released hemoglobin indicated RBC
membrane damage. Zero hemolysis and 100% hemolysis consisted
of RBC suspended in PBS and 0.2% Triton X-100, respectively. The
percentage of hemolysis was  determined as follows:
Hemolysis % =
(
As − A0 )× 100
A100 − A0
As corresponds to the absorbance of the treatment, A100 corre-
sponds to the absorbance of completely lysed RBC in 0.2% Triton
X-100, and A0 corresponds to the absorbance of zero hemolysis
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Fig. 2. Tris-Tricine electrophoresis of total soluble protein (1) and semi-puriﬁed
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Fig. 3. Hemolysis assay. Fresh RBC suspension was incubated with Pg-AMP1 at
different concentrations (circles) at 37 ◦C for 30 min. Release hemoglobin into super-eterologous Pg-AMP1 (2). Western blotting analyses of Pg-AMP1 (3) by using anti-
is  tag antibodies. M corresponds to molecular weight marker.
n PBS. The highest concentration of peptide that did not induce
emolysis was deﬁned as the ‘minimum hemolytic concentration’
MHC).
.9. Molecular modeling
Sequences of Pg-AMP1 and its recombinant form were submit-
ed to Local Meta-Threading-Server (LOMETS) [43]. However, no
igniﬁcant templates were found. Therefore, Monte-Carlo simu-
ations were performed by QUARK Ab initio server [45] in order
o create an initial structure. Based on this initial structure, Mod-
ller 9.9 [6] was used to generate 100 novel structures through
oop-reﬁnement sub-routine and structural information from Psi-
red [13] and Protein DisOrder prediction System (PrDOS) [25]. Ten
odels with minor discrete optimized protein energy (DOPE score)
or each sequence were selected and analyzed on PROCHECK [20]
nd protein structure analysis (ProSA) [42]. Models were visualized
n PyMOL (The PyMOL Molecular Graphics System, Version 1.4.1,
chrödinger, LLC).
. Results
.1. Expression of recombinant peptide
The expression of recombinant Pg-AMP1 peptide in BL21
DE3) after puriﬁcation yielded 2 mg  L−1 and the highest expres-
ion level was obtained after 4 h induction with 0.5 mM IPTG
data not shown). The Pg-AMP1 was fused to a histidine tag
roducing a 6.983 kDa peptide that showed a predicted pI of
.01(http://expasy.org/cgi-bin/pi tool). Thus, heterologous expres-
ion of peptide in E. coli strain BL21-(DE3) carrying the plasmid
BSKPg-AMP1 with His6 tag was demonstrated. Peptide was found
n the soluble fraction, thus facilitating the later stages of puriﬁca-
ion.
.2. Isolation of recombinant peptideThe Pg-AMP1 was ﬁrst fused to a histidine tag aiming to facil-
tate puriﬁcation. Soluble fraction of non-clariﬁed cell lysate was
irect loaded to IMAC (GE Crude His Trap FF) and western blot
nalysis conﬁrmed the presence of isolated peptide Pg-AMP1with
 molecular mass of approximately 14 kDa due dimer formation in
on-denaturating gel (Fig. 2).natant was  monitored in order to indicate the RBC membrane damage. PBS was  used
as  negative control (squares) and 0.2% triton X-100 was utilized as positive control
(triangles). Vertical bars correspond to standard deviation.
3.3. Bioassays
Aiming to investigate the antimicrobial activity of recombinant
Pg-AMP1 a bacterial trial was performed to understand the ability
of this peptide to inhibit microorganism proliferation. The recombi-
nant Pg-AMP1 clearly exhibited antimicrobial activities with lower
MICs against three Gram-positive bacteria tested (7.1 M).  Other-
wise, the deleterious activity against S. epidermides was  higher than
for the other pathogens evaluated, showing MIC of 100 g mL−1.
Moreover, the recombinant Pg-AMP1 showed antimicrobial activ-
ities against the four Gram-negative tested strains, with identical
MICs of 100 g mL−1 (Table 1), while control extracts did not show
antibacterial activity. In order to evaluate the Pg-AMP1 hemolytic
activity, the peptide was assayed in the presence of RBCs at con-
centrations of 200, 100 and 50 g mL−1. Pg-AMP1 was  able to lyses
RBCs only at higher concentration (200 g mL−1). Otherwise, no
signiﬁcant hemolysis was  obtained at lower concentrations (Fig. 3).
3.4. Molecular modeling
Since we  observed a modiﬁed activity of heterologous Pg-AMP1
in comparison to natural one, structural models were constructed
to elucidate this functional variation. The ﬁrst structure yielded
by QUARK was  composed of one N-terminal -helix, starting from
Pro5 until Arg17 for both sequences. The subsequent residues had no
well-deﬁned structure (data not shown). These ﬁrst structures are
in agreement with PsiPred secondary structure prediction, indicat-
ing an -helix (residues 9–19) and a random coil in the remaining
residues for both sequences. PrDOS indicates that structures are
mostly disordered. There are two chaotic regions in the structures,
the ﬁrst at the N-terminal and the second starting from residue
Tyr41 until C-terminal residue (Fig. 4). The other disordered region
is entailed due to the presence of several short side chain residues
such as glycine and serine, providing structural ﬂexibility, and there
are two  prolines near the C-terminal that also contribute protein
structure disorder. Proline residues lack an amide proton, essential
to stabilize a secondary structure, and proline residues inﬂuence
the preceding residue, favoring extended conformations [16,35].Therefore, given the structural ﬂexibility, Modeller’s loop-
reﬁnement sub-routine was  used in order to build novel structures.
It was applied on residues ranging from Tyr17 to Arg56 for natu-
ral Pg-AMP1; and from Tyr18 to His62 for recombinant Pg-AMP1.
298 L.S. Tavares et al. / Peptides 37 (2012) 294–300
Table 1
Bioassays of expressed Pg-AMP1 against different Gram-positive and Gram-negative human pathogenic bacteria. MIC corresponds to minimum inhibitory concentration. All
assays  were performed in triplicate.
Micro-organism MIC (g mL−1) Group Activity
Staphylococcus aureus MEC-A (ATCC 3359-1) 50 Gram-positive Bacteriostatic
Staphylococcus aureus (ATCC 2921-3) 50 Gram-positive Bacteriostatic
Staphylococcus epidermides (ATCC 1122-8) 100 Gram-positive Bacteriostatic
Klebsiella pneumoniae (ATCC 13866) 100 Gram-negative Bacteriostatic
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oPseudomonas aeruginosa (ATCC 27853) 100 
Escherichia coli (ATCC 11229) 100 
Escherichia coli (ATCC 35218) 100 
he ten best models for Pg-AMP1 show a DOPE score ranging
rom −1652.65503 to −1530.26282; for recombinant Pg-AMP1,
2335.47974 to −1945.35217. PROCHECK and ProSA analysis
hows that the generated structures are in agreement with dihe-
ral angles of known structures. For Pg-AMP1, Ramachandran plot
hows 91.7% of residues in favored (77.8%) plus allowed regions
13.9%) for the worst model and 100% of residues in favored (94.4%)
lus allowed regions (5.6%) for the best one. For recombinant Pg-
MP1, it shows 90.7% in favored (72.1%) plus allowed regions
18.6%) for the worst model and 100% of residues in favored (88.4%)
lus allowed regions (11.6%) for the best one. The overall G-factors
ary from −2.86 to −1.48 for Pg-AMP1 models; for recombinant
g-AMP1 models they vary from −0.19 to −0.07, which indicates
hat the models are ordinary structures. Z-scores on ProSA indicate
hat the structures have similar quality to that solved by magnetic
uclear resonance. They vary from −3.36 to −1.47 for Pg-AMP1 and
3.9 to −2.16 for recombinant Pg-AMP1.
The reﬁned structures have the same overall fold of the ﬁrst
tructure yielded by QUARK, one -helix, ranging from Pro4 to
yr19, and a random coil (Fig. 4); some structures from recombi-
ant Pg-AMP1 show an -helix that is one or two residues longer
t N-termini than Pg-AMP1. These data suggest that both Pg-AMP1
nd its recombinant form can assume several conformations, which
ay  have a great importance in its activity.
. Discussion
Several AMPs have being described as antibacterial and anti-
ungal, generally promoting pathogen membrane disruption or
ffecting DNA, RNA and\or protein synthesis and regulation
athways [9,16].  Nevertheless, different bacterial resistance mech-
nisms have being observed including modiﬁcation on membrane
ig. 4. Superimposition of ten best models of native Pg-AMP1 (A) and its recombinant for
oil.  The loop model with lower DOPE score is highlighted in red. (For interpretation of th
f  the article.)Gram-negative Bacteriostatic
Gram-negative Bactericidal
Gram-negative Bactericidal
surface charges, membrane proteins composition or proteolytic
enzymes secretion [2].  Perron et al. [29] related the resistance
development to pexiganan (an analog of magainin I) in E. coli and
Pseudomonas ﬂuorescens after 600–700 generations of exposition
to this peptide. By this way, Peschel and Sahl [30] suggested that
resistance to cationic peptides may  co-evolve with the pathogen.
In spite of the presence of AMPs mechanisms of resistance, these
compounds have emerged as promising candidates for antibiotics
development [11]. Some products using AMPs have been developed
by the pharmaceutical industry’s such as Mx-226, which is used as a
topical antibiotic for the prevention of catheter-related infections
and the pexigan, that makes part of a topical cream utilized for
diabetics foot ulcers treatment [9].
Among the AMPs, the GRPs have also shown potent antimicro-
bial activities. The antimicrobial peptide Pg-AMP1, a glycine-rich
AMP  from Psidium guajava that has 14 identiﬁed glycine residues
(22.5%) (Fig. 1), was  puriﬁed for the ﬁrst time by Pelegrini et al.
[28], showing clear antibacterial activity. The GRPs identiﬁed from
the mud  crab Scylla paramamosain also exhibited antimicrobial
activity against Gram-positive bacteria [12]. Nevertheless, other
functions have also been assigned to GRPs. Glycine-rich peptides
isolated from Avena sativa and Ginkgo biloba showed a chitin bind-
ing domain that provides inhibitory properties against ﬁlamentous
fungi [4].  Moreover, the insect GRP tenecin-3 was  able to control
Candida albicans cells [9] and SK84 from Drosophila virilis showed
antimicrobial and anti-cancer cell activities [23].
The native Pg-AMP1 showed potent antimicrobial activities but
its production from guava seeds was  insufﬁcient for biopharma-
ceutical production [28]. This fact is extremely common when
native plants are involved, showing peptide expression elicited by
environment changes, seasonality and other environmental uncon-
trolled factors. In order to overcome such problems, synthetic or
m (B). The overall structure comprises an N-terminal -helix followed by a random
e references to color in this ﬁgure legend, the reader is referred to the web version
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ecombinant peptides are excellent biotechnological alternatives
16].
In the present work the recombinant Pg-AMP1 was  ﬁrst fused to
 single histidine tag to reduce the costs and time for isolation. His6
ag protein may  cause proteolysis protection, solubility and gener-
lly does not affect protein folding [21]. Moreover, small amounts of
nclusion bodies were observed during Pg-AMP1 expression, prob-
bly produced by insoluble protein (data not shown). Generally,
ukaryotic small proteins such as interleukins and insulin, when
xpressed in a prokaryotic system, may  form similar aggregates
17]. The main cause of incorrect protein folding seem to be the
ow number of chaperone molecules that results in the formation
f inclusion bodies [21].
The recombinant Pg-AMP1 showed different activity from the
ative form, including activity against Gram-positive S. aureus
Table 1). These data suggest that addition of some amino acid
esidues for cloning and expression may  alter the main function of
g-AMP1. Some authors proposed that the histidine tag may  alter
econdary conformation and its biological activity [14]. Further-
ore, hemolytic assays showed RBCs lysis only at higher Pg-AMP
oncentrations suggesting that peptide shows higher afﬁnity to
rokaryotic cell membranes. This speciﬁcity may occurs due to a
educed quantity of negatively charged lipids and also the choles-
erol presence on human cells [44].
The molecular models show that the histidine tag does not
enerate clear structural modiﬁcations (Fig. 4). The GRPs are char-
cterized by glycine repeat domains, which confer them high
exibility and may  act as Velcro type during protein–lipid inter-
ctions [24]. According to Sachetto-Martins [32] glycine repeats
re accompanied by Tyr, His, Arg, Asn or Glu affecting peptide
ydrophobicity. In Pg-AMP1, glycine repeats are interspersed by
yrosines (Y18GY20GGY23), (Y28GGGY32G), arginine (GR36G) and
lutamine (GQ42G) residues (Fig. 1). Glycine repetitions in the
equence provide structural ﬂexibility as previously described
28], allowing it to assume diverse loop conformations like those
bserved in molecular modeling (Fig. 4). In this case the utilization
f several structures is particularly important for a better charac-
erization of its alternative conformations. Through the molecular
odeling method employed in this study, several answers could
e reaching about Pg-AMP1 structures. In fact, there are several
ossible conformations for Pg-AMP1, without a tendency to a spe-
iﬁc fold type. In contrast to a previous report [28], the molecular
odel of Pg-AMP1 here reported shows only the N-termini -helix,
ndicating that the probable structure could be more ﬂexible than
reviously described.
The same scenario was assumed for the recombinant Pg-AMP1
tructural prediction, in which extremely ﬂexible structures were
bserved. Carson et al. [3] showed that the His6 tag normally does
ot alter the structure of recombinant proteins. In our predic-
ions, the His6 tag takes on a random coil conformation, as well as
he C-terminal of predicted Pg-AMP1structure. Otherwise, despite
he overall structure maintenance, the His6 tag seems to alter the
g-AMP1 activity, since the recombinant protein is active against
acteria in which the native form is completely inactive, such as
ram-positive bacteria S. aureus and S. epidermides. These data
ndicate that the His6 tag may  alter the mechanism of action of
g-AMP1. The His6 tag probably increases the afﬁnity of recom-
inant Pg-AMP1 to bacterial membranes, providing an stronger
nteraction with anionic membranes, due to the increase in pos-
tive C-terminal charges. The net charge seems to be an essential
roperty to antimicrobial activity. Dathe et al. [5] had conducted
n study generating several analogs of magainin. The analogs were
esigned for keeping several properties such as hydrophobicity and
elix propensity, changing only the net charge. The more active
nalogs were the ones with charges higher than +5. In this view,
he His6 tag could generate a similar effect to observed in the
[
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magainin analogs developed by Dathe et al. [5].  Bearing this in mind,
we propose that the N-terminal is responsible for membrane bind-
ing, independently of the helix being one or two  residues longer
as observed in some models of recombinant Pg-AMP1, acting as a
membrane anchor mediated by the three arginine residues. Sub-
sequently, the random coil starts to interact with phospholipids,
destabilizing the membrane. Metaphorically, this peptide would
acts like a chain whip, an Asian melee weapon. The recombinant
protein would be a chain whip with a sharper metal dart, the His6
tag (Fig. 4).
In conclusion, it was observed that heterologous expression of
Pg-AMP1 conserved its antimicrobial activity, enabling this pep-
tide to be a candidate for production of antimicrobial compounds.
Moreover, theoretical modeling clearly shows that the proposed
structure is extremely variable due to ﬂexibility of high glycine
content. The presence of the His6 tag seems to not show clear struc-
tural modiﬁcations according theoretical studies here proposed
and probably caused smooth antimicrobial activities modiﬁcations.
In summary peptide engineering could help, in a near future, to
ﬁnd the essential Pg-AMP1 regions involved on antimicrobial activ-
ity. Once that this regions have being found, it will be possible to
enhance the bactericidal activity by switching amino acid residues
and also reduce the costs by reducing Pg-AMP1 length, leading to
a possible application on industrial drug development.
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